Overview

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

Status:
Completed

Trial end date:
2018-02-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.

Phase:

Phase 3

Details

Lead Sponsor:

Esperion Therapeutics
Esperion Therapeutics, Inc.

Treatments:

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
Ezetimibe